Skip to main content
Clinical Trials/KCT0005453
KCT0005453
Withdrawn
N/A

The Efficacy of Early Screening and Treatment of Depression with Selective Serotonin Reuptake Inhibitor (SSRI) in Adult Glioma Patient

Asan Medical Center0 sites112 target enrollmentTBD
ConditionsNeoplasms

Overview

Phase
N/A
Intervention
Not specified
Conditions
Neoplasms
Sponsor
Asan Medical Center
Enrollment
112
Status
Withdrawn
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
August 15, 2022
Last Updated
last year
Study Type
Interventional Study
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\)Understand and voluntarily sign an informed consent document prior to any study related assessment/procedures are conducted
  • 2\)First time histologically confirmed diagnosis of glioma (resection or biopsy)
  • 3\)Age \=18 years and \= 85 years
  • 4\)Glasgow Coma Score (GCS) 5\-15

Exclusion Criteria

  • 1\)Unable to perform the screening test due to the neurologic deficit
  • 2\)Evidence of ongoing acute brain bleeding on CT or MRI
  • 3\)Previously confirmed diagnosis of a benign, low\- or high\-grade brain tumor
  • 4\)Diagnosis of systemic cancer other than glioma (breast cancer, lung cancer, gastric cancer, colon cancer etc.)
  • 5\)Currently taking antidepressant drugs
  • 6\)Previously suffered from depression in the past or within 5 years of diagnosis, and currently do not receive drug therapy
  • 7\)Taking following drugs: MAO (monoamine oxidase) inhibitor, linezolid, thioridazine, mesoridazine, pimozide, tizanidine, terfenadine, astemizole or cisapride
  • 8\)SSRI allergic history
  • 9\)On antiplatelets or anticoagulation agents (aspirin, clopidogrel, cilostazol, heparin, warfarin ?vitamin K antagonist?, DOAC ?Direct Oral Anticoagulants?)
  • 10\)On non\-steroidal anti\-inflammatory drug (NSAID)

Outcomes

Primary Outcomes

Not specified

Similar Trials